QMF149 150/80 μg
CQVM149B2303
Phase 3 small_molecule completed
Quick answer
QMF149 150/80 μg for Mild Asthma is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Mild Asthma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed